CYAD - セリアド （Celyad SA） セリアドCYADのチャート
CYADの企業情報
| symbol | CYAD |
|---|---|
| 会社名 | Celyad SA （セリアド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- セリアドはベルギ―のバイオ医薬品企業。主に心不全や心筋梗塞などの心臓疾患の治療法の発見、開発、商業化に従事する。バイオ治療薬を心臓の筋肉に注入するためのカテ―テル「C-CATHez」を提供。また、慢性心不全や虚血性心筋症の治療向けに臨床段階の主力薬剤である「C-Cure」を提供する。新薬候補にはタンパク質ベ―スの薬剤も扱う。 |
| 本社所在地 | Rue Edouard Belin 12 Mont-Saint-Guibert 1435 BEL |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 39264 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 76人 |
| url | www.C3BS.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cyad |
| adr_tso | 883561 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 25 |
| 時価総額（marketcap） | 22089025 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
CYADのテクニカル分析
CYADのニュース
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights 2022/05/05 22:12:00 GlobeNewswire
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents and net cash burn during the first quarter of 2022 should have been stated as €20.5 million ($22.9 million) and €9.5 million ($10.6 million), respectively, not €20.6 million ($23.0 million) and €9.4 million ($10.5 million), respectively. The corrected release follows:
CORRECTING AND REPLACING: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights 2022/05/05 21:31:00 Business Wire
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: This replaces the announcement made at 22:01 CEST on 5 May due to the following corrections: Updated ''First Quarter 2022 Financial Review'' section. CELYAD ONCOLOGY ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) ther
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights 2022/05/05 20:01:00 Business Wire
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended March 31, 2022. “The first quarter of 2022 brought us both challenge
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights 2022/03/24 20:02:00 Business Wire
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced its financial results for the fiscal year 2021 ended December 31, 2021 and provided a business update. "This is a transformative time for Celyad Oncology as we work
FDA Slaps Clinical Hold On Celyad''s Phase 1 Colorectal Cancer Trial 2022/03/02 14:25:37 Benzinga
The FDA has issued a clinical hold on Celyad Oncology SA''s (NASDAQ: CYAD ) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects. As previously disclosed, the Company … Full story available on Benzinga.com
Celyad Oncology SA: Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) 2021/06/30 05:04:00 FinanzNachrichten
Regulatory News: Celyad Oncology SA (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies f
Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) 2021/06/30 05:00:00 Wallstreet:Online
Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on June 30, 2021, a capital increase of 306,800 new shares of the Company through Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor, and its Open
H.C. Wainwright Reaffirms Their Buy Rating on Celyad (CYAD) 2021/06/14 10:27:55 Smarter Analyst
In a report released today, Edward White from H.C. The post H.C. Wainwright Reaffirms Their Buy Rating on Celyad (CYAD) appeared first on Smarter Analyst .
Celyad shares surge ahead of upcoming multiple myeloma study poster presentation 2021/05/13 12:11:01 Seeking Alpha
Celyad (CYAD) Receives a Buy from H.C. Wainwright 2021/05/13 10:17:23 Smarter Analyst
In a report released today, Edward White from H.C. The post Celyad (CYAD) Receives a Buy from H.C. Wainwright appeared first on Smarter Analyst .
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today 2021/01/19 10:50:00 Benzinga
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, …
Cell And Gene Therapy Market Research, Development, Top Companies, Trends and Growth 2020 to 2030 | Celyad, Cook MyoSite, Cytori Therapeutics, Ferring Pharmaceuticals, Gamida Cell 2020/10/27 04:53:44 OpenPR
The Business Research Company offers "Cell And Gene Therapy Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective
Trump enfonce la bourse de Toyo | Dividende intérimaire pour Ageas 2020/08/07 05:28:05 L'Echo
La bourse de Hong Kong chute, alors que Trump fait monter la pression contre TikTok et WeChat. Ageas communique le montant de son dividende intérimaire. Celyad et Galapagos à tenir à l'oeil.
Celyad Oncology publie ses résultats financiers du premier semestre 2020 et les faits marquants du second trimestre 2020/08/06 20:00:00 Business Wire
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), une société de biotechnologie au stade c
"Les marchés attendent de voir quelle forme aura le plan de relance US" 2020/08/06 09:46:39 L'Echo
Les marchés européens se replient, dans un climat général de prudence alimentée par les perspectives de la BoE. VGP ajuste le tir sur ses résultats et bondit en bourse. Déferlante de chiffres trimestriels (Adidas, Celyad, Fagron, Galapagos, ING, KBC, Lufhtansa, Montea…).